From the Pines Manor to the White House!
Larry Ellison, chairman of Oracle, recently unveiled groundbreaking Artificial Intelligence (AI) applications in healthcare at the White House’s Stargate Project launch in January:
1. Personalized cancer vaccines: AI could potentially create customized mRNA vaccines for individual cancer patients within 48 hours.
2. Early cancer detection: AI can identify small tumor fragments in the bloodstream through a simple blood test.
3. Rapid vaccine production: After gene sequencing of the tumor, AI can design a targeted vaccine, which can be manufactured quickly using robotic systems.
Key points about the anticipated process:
– Begins with a blood test to detect tumor fragments. THIS COMES FROM THE RESEARCH THIS FOUNDATION HAS SUPPORTED!
– AI assists in early identification of these fragments
– Gene sequencing of the tumor follows
– AI designs a personalized vaccine based on the sequencing
– Robotic systems can manufacture the vaccine in about two days
Important research that this Foundation has supported has been the work of David Lyden, MD, PhD. Dr. Lyden is a renowned physician-scientist and a leading expert in cancer biology and metastasis research. He holds positions as a Professor of Pediatrics and Cell & Developmental Biology at Weill Cornell Medicine and is an attending physician at NewYork-Presbyterian Hospital. Dr. Lyden’s groundbreaking research focuses on how cancer spreads (metastasis) and the role of extracellular vesicles, including exosomes, in tumor communication and progression. He has contributed significantly to research on blood tests for cancer detection, particularly through his work on exosomes and extracellular vesicles. Key Contributions:
- Exosomes as Cancer Biomarkers:
Dr. Lyden’s research demonstrated that tumor-derived exosomes (tiny vesicles released by cells) carry genetic and protein information that can be detected in the bloodstream. These exosomes help prepare distant sites for metastasis and provide a “liquid biopsy” approach to detect cancer. - Liquid Biopsy Development:
His work has paved the way for blood tests that analyze exosomes to identify cancer types, monitor disease progression, and predict responses to treatment. By analyzing the cargo of exosomes (DNA, RNA, and proteins), researchers can gather crucial information about the presence and nature of tumors without invasive tissue biopsies. - Clinical Implications:
These discoveries are being explored for use in diagnosing cancers at earlier stages and tracking the effectiveness of treatments in various types of cancers, including aggressive metastatic cancers.
Your support helps this happen! Follow us as we get ready to celebrate our progress this November 8, 2025: https://fifthdistrictahepacrf.com/